Sardar Khan, MD
Gastroenterology · Houston, TXNPI 1104826452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 58.1% of the total. Reporting peaked in 2021 at $201 and has fallen 56.3% since, to $88 in 2025. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 49 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$557
- Gilead$186
- Pfizer$68
- Lilly USA, LLC$42
- Abiomed$25
- Capsovision, Inc.$22
- plus $58 from 4 others
Across 5 payments — averaging $4849.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$24K
What the payments were for
- Food & beverage$95099%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $557 |
| Gilead | 10 | $186 |
| Pfizer | 4 | $68 |
| Lilly USA, LLC | 2 | $42 |
| Abiomed | 1 | $25 |
| Capsovision, Inc. | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$958 in reported general payments places this provider in the 25th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 161 | $3,666 |
| Pantoprazole Sodium | 64 | $399 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $201 |
| Metformin Hcl | 15 | $116 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.